AMGEN Inc.

NASDAQ:AMGN   3:59:59 PM EDT
234.01
-1.35 (-0.57%)
4:45:56 PM EDT: $233.83 -0.18 (-0.08%)
Products

Amgen Says FDA Approved Tezspire In The U.S. For Severe Asthma

Published: 12/17/2021 21:46 GMT
AMGEN Inc. (AMGN) - FDA Approves Tezspire™ (tezepelumab-ekko) in the U.S. for Severe Asthma.
Amgen -fda) Approved Co, Astrazeneca's Tezspire for Add-on Maintenance Treatment of Adult, Pediatric Patients 12 Years and Older With Severe Asthma.